Sole Source - Cepheid GeneXpert Tests/Equipment
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Defense Health Agency (DHA), specifically the 96th Medical Group (MDG) at Eglin Air Force Base, has issued a Sole Source Justification for the procurement of Cepheid GeneXpert systems and reagents. This action is based on a determination that Cepheid, Inc. is the only responsible source capable of providing the required proprietary equipment and associated test kits. The intent is to award a Firm Fixed Price (FFP) task order to Cepheid, Inc.
Scope of Work
The requirement includes the procurement of a closed-system Real-Time Polymerase Chain Reaction (RT-PCR) analyzer with rapid detection capabilities. Key equipment includes:
- One (1) GeneXpert XVI R2, 16 Module, Desktop, 10C
- One (1) GeneXpert IV R2, 4 Module, Desktop, 10C
- Two (2) UPS for GX1 up to GX16 Systems, 110V
- Two (2) B&W Printer for GeneXpert and Smart cycle
Required reagents per contract year include: 200 XP3COV2/FLU/RSV-10 kits, 24 GXMRSA-100N-10 kits, 120 XPRSMVP-10 kits, and 180 XPRSTREPA-10 kits. Services encompass telephone technical support (Monday-Friday, 0800-0000) and routine instrument repair, preventive maintenance, and calibrations.
Contract & Timeline
- Type: Firm Fixed Price (FFP) task order.
- Period of Performance: 1 March 2026 through 28 February 2031, including option periods.
- Set-Aside: Sole-source award to Cepheid, Inc.
- Published: March 5, 2026.
Evaluation
This document serves as a justification for a sole-source award and is not a solicitation for proposals. A prior notice of intent was posted on January 30, 2026, inviting responsible sources to submit business identification and capability statements by February 14, 2026, if they believed they could meet the requirement.
Additional Notes
The Cepheid GeneXpert system is the current instrumentation in use at the 96th MDG and is designed exclusively for Cepheid Xpert assay applications. The system is validated with the Military Health System (MHS) GENESIS Electronic Medical Record (EMR). Market research confirmed Cepheid as the original equipment manufacturer and sole provider of the proprietary GeneXpert system and reagents, supported by a sole source letter from Cepheid dated January 20, 2026.